HanAll Biopharma Recorded KRW 22.1 Billion, KRW 1 Billion, a..
HanAll Biopharma(KRX: 009420.KS) today
announced that its Chinese partner, Harbour BioMed, had initiated the first
dosing of patient of HL161(INN: Batoclimab) in both myasthenia gravis(MG) and Immune
thrombocytopenic purpura(ITP).
HL161 is a novel antibody drug for treating
autoimmune diseases by inhibiting FcRn, which plays a role of prolonging the
half-life of the IgG antibody, thus promoting breakdown of pathogenic
autoantibodies in the system. In 2017, HanAll Biopharma licensed rights to
develop and commercialize HL161 in the North American, Central and South
American, European, Middle Eastern, and North African regions to Roivant
Sciences of Switzerland(currently its subsidiary, Immunovant), and for the
China region(including Hong Kong, Taiwan, and Macao) to Harbour BioMed of
China. Since then, the three companies have been accelerating global clinical
development of HL161 through cooperation based on a global alliance.
For HL161, a global clinical trial is being
conducted across countries in five indications, such as myasthenia gravis,
immune thrombocytopenic purpura, thyroid eye disease, warm antibody autoimmune
hemolytic anemia, and neuromyelitis optica spectrum disorder, along with
clinical trials in China. With the mechanism of action to break down and remove
autoantibodies, HL161 is expected to be a multilayer drug to treat various
autoimmune diseases.